In in vitro analysis, CCL20 greatly enhanced the invasive ability of triple‐negative breast cancer cell lines by increasing the secretion of matrix metalloproteinase (MMP)‐2 and MMP‐9; meanwhile, anti‐CCL20 antibody by intraperitoneal injection in a mouse breast cancer model could effectively inhibit the occurrence of bone metastases.236. Here, CCL20 is linked to breast carcinoma.